MOTS-C
Mitochondrial-derived peptide studied for AMPK pathway activation, metabolic regulation, and exercise mimetic effects.
Product information
You save €13.00 on this presentation — an extra 10% off when you pay with crypto.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically within the 12S rRNA gene. Discovered by Changhan David Lee at the University of Southern California in 2015, it was one of the first mitochondrial-derived peptides (MDPs) identified. MOTS-C is unique because it is encoded by mitochondrial DNA but acts on nuclear gene expression, representing a key retrograde signalling molecule from mitochondria to the nucleus.
Mechanism of Action
MOTS-C activates the AMPK (AMP-activated protein kinase) pathway by inhibiting the folate-methionine cycle in the de novo purine synthesis pathway, leading to accumulation of AICAR — an endogenous AMPK activator. Once activated, AMPK triggers a cascade that enhances glucose uptake, increases fatty acid oxidation, and promotes mitochondrial biogenesis. MOTS-C also translocates to the nucleus under metabolic stress, where it regulates adaptive nuclear gene expression through interaction with the antioxidant response element (ARE).
Research Applications
- AMPK pathway activation and metabolic signalling
- Exercise mimetic research and skeletal muscle biology
- Mitochondria-to-nucleus retrograde signalling studies
- Glucose homeostasis and insulin sensitivity models
- Ageing and mitochondrial-derived peptide research
Reconstitution calculator
Enter your reconstitution to get the draw volume for MOTS-C.
Pull the plunger to 5.0 units on a 1 ml U‑100 syringe0.050 ml · 5.00 mg/ml · 40 doses per vial
Concentration = peptide mass ÷ water volume. Unit readings assume U-100 insulin syringes, graduated 100 units per millilitre. For laboratory calculation only — not dosing guidance.